No Data
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $177
Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management
Mizuho Adjusts Price Target on Quest Diagnostics to $177 From $174, Keeps Outperform Rating
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
Is Quest Diagnostics (NYSE:DGX) Using Too Much Debt?
No Data
